Article
Alcohol and paracetamol
- Garry G. Graham, Kieran F. Scott, Richard O. Day
- Aust Prescr 2004;27:14-5
- 1 February 2004
- DOI: 10.18773/austprescr.2004.009
There are concerns that therapeutic doses of paracetamol may be hepatotoxic in patients who regularly drink moderate to large amounts of alcohol. Critical examination of case histories reveals that overdoses of paracetamol were responsible for the hepatotoxicity in many cases. Experimental studies in which paracetamol was taken for short periods also show no interaction. Paracetamol is therefore a suitable analgesic for patients who regularly drink moderate to large amounts of alcohol but, as with all patients, care should be taken to minimise the chances of overdose.
It is well known that overdoses of paracetamol are hepatotoxic. There have been claims that alcohol potentiates this hepatotoxicity to such an extent that therapeutic doses of paracetamol become hepatotoxic in some patients. The so-called 'alcohol-paracetamol syndrome' describes the hepatotoxicity which is said to occur from the ingestion of therapeutic doses of paracetamol in moderate to heavy drinkers of alcohol.1
The belief about the hepatotoxicity of paracetamol in people who drink alcohol regularly is shared by the USA Food and Drug Administration (FDA) which now requires that paracetamol sold in the USA be labelled with the warning stating that, 'If you consume 3 or more alcoholic drinks every day, you should ask your doctor whether you should take acetaminophen (paracetamol) or other pain relievers/fever reducers. Acetaminophen may cause liver failure.' Canada has also issued a warning about the possibility of liver damage in heavy users of alcohol who take more than the recommended dose of paracetamol.
Several reasons for the warnings about the hepatotoxicity of paracetamol may be put forward and examined:
Hepatotoxicity from therapeutic doses of paracetamol is unlikely in patients who consume moderate to large amounts of alcohol daily. However, patients with severe alcoholism should be instructed or supervised about the correct dosage of paracetamol. The depression often associated with alcoholism may make them more likely to take an overdose of paracetamol. Furthermore, the memory loss often seen in severe alcoholism may make patients unaware of having taken more than the recommended dose.
In the UK limiting the single sale of paracetamol tablets or capsules to 16 in general stores and 32 in pharmacies has been correlated with a reduction in the number of overdoses with paracetamol. Restricting the availability of paracetamol to patients with severe alcoholism and/or depression associated with alcohol abuse may similarly be associated with a decreased number of overdoses of paracetamol.
Overdoses of paracetamol are a major problem. The occurrence of hepatotoxicity in patients who consume alcohol regularly and who take therapeutic doses of paracetamol is a very contentious topic. At this stage, paracetamol appears to be a reasonable analgesic or antipyretic drug to use in compliant patients who consume alcohol regularly. However, longer-term controlled studies are still required to clarify further the safety of paracetamol when taken regularly in combination with moderate to large amounts of alcohol.
After a recent review, the Therapeutic Goods Administration's decision that no warning regarding alcohol should be added to labels on paracetamol products seems reasonable.8
E-mail: [email protected]
Department of Clinical Pharmacology, St Vincent's Hospital and School of Medical Sciences, University of New South Wales, Sydney
Department of Clinical Pharmacology, St Vincent's Hospital and School of Medical Sciences, University of New South Wales, Sydney
Department of Clinical Pharmacology, St Vincent's Hospital and School of Medical Sciences, University of New South Wales, Sydney